FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors
Drug manufacturer Hutchmed said the FDA sent the company a complete response letter indicating that the agency requires a multiregional clinical trial before approving the drug in the US.
News Alerts
source https://www.medscape.com/viewarticle/973228?src=rss
News Alerts
source https://www.medscape.com/viewarticle/973228?src=rss
Comments
Post a Comment